203
Participants
Start Date
July 31, 2010
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
Retigabine IR
Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
GSK Investigational Site, Sofia
GSK Investigational Site, Sofia
GSK Investigational Site, Koebenhavn Oe
GSK Investigational Site, Glostrup Municipality
GSK Investigational Site, Leuven
GSK Investigational Site, Liège
GSK Investigational Site, Plovdiv
GSK Investigational Site, Dianalund
GSK Investigational Site, Pleven
GSK Investigational Site, Ghent
GSK Investigational Site, Bangkok
GSK Investigational Site, Berlin
GSK Investigational Site, Genoa
GSK Investigational Site, Kiel
GSK Investigational Site, Madrid
GSK Investigational Site, Bielefeld
GSK Investigational Site, Rennes
GSK Investigational Site, Marburg
GSK Investigational Site, Vigo
GSK Investigational Site, Khon Kaen
GSK Investigational Site, Bologna
GSK Investigational Site, Seville
GSK Investigational Site, Valencia
GSK Investigational Site, Dnipro
GSK Investigational Site, Siena
GSK Investigational Site, Bonn
GSK Investigational Site, Nancy
GSK Investigational Site, Pisa
GSK Investigational Site, Lille
GSK Investigational Site, Torrette Di Ancona
GSK Investigational Site, Kharkiv
GSK Investigational Site, Odesa
GSK Investigational Site, Strasbourg
GSK Investigational Site, Oleksandrivka Village, Odesa
GSK Investigational Site, Lyon
GSK Investigational Site, Stuttgart
GSK Investigational Site, Foggia
GSK Investigational Site, Tübingen
GSK Investigational Site, Kehl-Kork
GSK Investigational Site, Lviv
GSK Investigational Site, Donetsk
GSK Investigational Site, Limoges
GSK Investigational Site, Reggio Calabria
GSK Investigational Site, Songkhla
GSK Investigational Site, Palermo
GSK Investigational Site, Luhansk
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Belgorod
GSK Investigational Site, Krasnodar
GSK Investigational Site, Kazan'
GSK Investigational Site, Samara
GSK Investigational Site, Rome
GSK Investigational Site, Rome
GSK Investigational Site, Breda
GSK Investigational Site, Heemstede
GSK Investigational Site, Heeze
GSK Investigational Site, The Hague
GSK Investigational Site, Iława
GSK Investigational Site, Katowice
GSK Investigational Site, Krakow
GSK Investigational Site, Warsaw
GSK Investigational Site, Warsaw
GSK Investigational Site, Smolensk
GSK Investigational Site, Poltava
Lead Sponsor
GlaxoSmithKline
INDUSTRY